EUCTR2005-005430-12-DE进行中（未招募）不适用
Randomised, double-blind, placebo-controlled study of topicalGW842470X formulation in adult patients with moderate atopicdermatitis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 190
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Adult men or women.
- •Women will be eligible to enter the study if they are:
- •-Not pregnant or nursing.
- •-Of non-child-bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is post-menopausal or surgically sterile).
- •-Of child-bearing potential and using an appropriate method of contraception
- •with a documented failure rate of less than 1% per year for the duration of the
- •study and for 1 month after the last administration of investigational product
- •2. Aged 18 to 65 years.
- •3. Body weight = 50 kg (110 lbs) and BMI within the range of 17.5-32 kg/m2 inclusive where BMI =(weight in kg)/(height in meters)*2
- •4. Subjects with a diagnosis of atopic dermatitis but who are otherwise healthy. Healthy is defined as individuals who are free from significant cardiac, pulmonary, gastrointestinal, hepatic, renal, haematological, neurological and psychiatric disease as determined by history, physical examination and screening investigations.
- •5. Subjects must have body surface area (BSA) disease involvement of >5% as assessed by the rule of nines method.
- •6. Patients must be willing to wash out from current active therapy for at least 10 days prior to Day 1.
- •7. Capable of giving informed consent, which includes compliance with the requirements and restrictions listed in the consent form
- •8. A signed and dated written informed consent is obtained from the subject.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. The subject presents with any systemic disorder or active skin disease (other than atopic dermatitis) (e.g. psoriasis) that would in any way confound interpretation of the study results or subjects who present with scars, moles, tattoos, body piercings, sunburn in the test area which could interfere with the assessment of lesions at screening.
- •2. The subject has atopic dermatitis restricted to the face, the feet or the hands only.
- •3. The subject has a current complication of atopic dermatitis such as erythroderma or overt bacterial or viral infection for which treatment with anti-infectives are
- •4. History of recent (<1 month) active or presence of current superficial skin infections of viral aetiology such as herpes simplex, or varicella.
- •5. The subject has been diagnosed as having contact dermatitis in area of target lesions, seborrheic dermatitis and/or occupational eczema at predilection sites of atopic dermatitis.
- •6. The subject has had topical or transdermal treatments, such as but not limited to retinoids, nicotine or hormone replacement therapies, on or near the intended site of application within 14 days prior to first application of study medication. Use of other topical preparations such as those containing vitamins, supplements or herbal within 14 days prior to application.
- •7. The subject has had systemic treatment for atopic dermatitis (including PUVA or UVB) within 14 days of the first dose of study medication.
- •8. Foreseeable intensive UV exposure during the study (solar or artificial). Subjects must not be exposed to intense direct sunlight for long periods, and must not use skin tanning devices (e.g. sunbed) for the duration of the study.
- •9. The subject has used topical treatment with tar or any corticosteroid or oral treatment with any corticosteroids within 10 days of the first dose of study medication.
- •Additionally, subjects who have taken oral immunosuppressants (e.g. cyclosporine azathioprine) within 1 month of the first dose of study medication.
- •10. History of cutaneous photodisorder, such as photoallergic reaction or polymorphic light eruption.
- •11. History of allergy to components of test medications, including vaseline, emollient or specific soap and adhesives to be used in the study.12. History of clinically significant cardiovascular, neurological, renal, endocrine or haematological abnormalities.
- •13. Subjects with a history of diaphoresis/excessive sweating not restricted to palms or face.
- •14. Subjects with a smoking history of >10 cigarettes per day in the last 3 months.
- •15. Subjects taking dietary and herbal supplements, high strength mineral supplements (specifically Selenium (>75ug per day) and Zinc (>15mg per day)) or antiinflammatory drugs (e.g. corticosteroids, immunosuppressive drugs, or antihistamines).
- •The use of stable therapy for 6 months for subjects with well controlled chronic disease (eg. hypertension, depression, anxiety, acid reflux, etc) and the use of multi-vitamin supplements are permitted at the discretion of the Principal Investigator/physician designee in consultation with the Medical Monitor where there is a question.
- •16. As a result of the medical interview, physical examination or screening investigations, the physician responsible (Principal Investigator or delegated physician) considers the subject unfit for the study.
- •17. The subject has plasma concentrations of aspartate-, alanine aminotransferase, total bilirubin, or alkaline phosphatases higher than the upper li
研究者
相似试验
进行中（未招募）
1 期
Effects of EPA-FFA on polypectomy in familial adenomatous polyposis.Familial Adenomatous Polyposis (FAP)MedDRA version: 20.1Level: LLTClassification code 10059327Term: Familial adenomatous polyposisSystem Organ Class: 100000004850EUCTR2017-002809-34-CZSLA Pharma (UK) Ltd204
进行中（未招募）
不适用
Randomised, double-blind, placebo-controlled study to investigate the efficacy and safety of a herbal combination product, Eviprostat N, in the treatment of moderate LUTS associated with benign prostatic hyperplasia” - EVE 2004/01Patients with moderate LUTS (Lower Urinary Tract Symptoms) associated with benign prostatic hyperplasiaMedDRA version: 7.0Level: LLTClassification code 10004446EUCTR2004-002901-57-DEPharmazeutische Fabrik Evers & Co. GmbH326
已完成
不适用
Randomised, double-blind, placebo-controlled study to evaluate the safety, tolerability, immunogenicity and shedding of live-attenuated RSV vaccine in healthy adults<br>NL-OMON47495Intravacc48
进行中（未招募）
1 期
Clinical trial to compare APD421 (amisulpride) against a placebo for the treatment of patients feeling sick or being sick after an operation, who have previously been given preventative anti-sickness medicine.Post-operative nausea and vomitingMedDRA version: 19.0Level: PTClassification code 10066962Term: Procedural nauseaSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsEUCTR2015-003992-30-DEAcacia Pharma Ltd700
已完成
1 期
Safety and tolerability of increasing doses of ZY-19489 compared to placebo in healthy volunteers.MalariaACTRN12619000127101Cadila Healthcare Limited48